ALK and non-small cell lung carcinoma: In addition, non-small cell lung cancer (NSCLC) patients with activating mutations, such as epidermal growth factor receptor mutations (EGFR) or anaplastic lymphoma kinase (ALK) translocations, may have longer survival than wild-type patients [9].